Zeus is going to dominate the industry

Quote
Anonymous said:
LOL - drinking the last place, least admired, least respected CL company 'Puhleeze Jesus, let us finally have a half-ass successful product' Kool Aid?

BTOD - bringing up last place in its 'segment' and misrepresented as SiHy to OD's. PV2 'hailed' as a N&D beater? Turned into an abysmal flop. BT Solution another failure already forced to go generic.

No fears or worries about Ultra. Bring it.
Click to expand...

Last place..... Least admired. Agreed!

However, ultra is a world better than that steaming pile air optix line. Will give biofinity a run for its money.

The other poster is right. Bnl ticked off a whole bunch of non affiliated ODs by whoring out pv2 to walmart.
 






Ultra is a day late and a dollar short to the party, like everything else B&L does.
BTOD was supposed to be a contender, ended up a lame pretender. Ultra will end the same as the two big boys reveal advances beyond Ultra and Biofinity over the next 18 months. Be on the lookout for Sauflon to eat B&L alive.
 






Anonymous said:
It is funny how you think you know everything. But you don't

PV2 was a stop gap, BTOD is a different market segment, and is not a failure.

Zeus=Ultra, always has been. Zeus was the code name gimmick from a guy with a god complex. Ultra is the name that customers will know it buy. But Valeant wasn't smart enough to understand code names, so they started talking about Zeus in the news.
If Ultra is a failure, B+L Vision Care is dead. But short of a massive recall Ultra will be huge (for Bausch). Might not make us #1 in SiHy manufacturer, but it will be much bigger than PV/PV2 ever was, for a fraction of the cost to manufacture, but at a higher retail price. New Jersey is really gonna like revenue and profits.

Also, given the amount of money spent on Ultra, and the fact that it is the final product to come out of Vision Care R&D it will likely be a huge beacon on Valeant's profitability.
If Ultra sales are strong by the end of the summer, buy Valeant. If they are soft, the house of cards will collapse. Neither Bausch or Valeant can survive without Ultra (it will be 5-10% of Valeant's Revenues by 2016) and it will be the calling card that gets salesmen back into the ODs office.
Click to expand...

http://m.youtube.com/watch?v=DgqzE5M5trM
 






Anonymous said:
It is funny how you think you know everything. But you don't

PV2 was a stop gap, BTOD is a different market segment, and is not a failure.

Zeus=Ultra, always has been. Zeus was the code name gimmick from a guy with a god complex. Ultra is the name that customers will know it buy. But Valeant wasn't smart enough to understand code names, so they started talking about Zeus in the news.
If Ultra is a failure, B+L Vision Care is dead. But short of a massive recall Ultra will be huge (for Bausch). Might not make us #1 in SiHy manufacturer, but it will be much bigger than PV/PV2 ever was, for a fraction of the cost to manufacture, but at a higher retail price. New Jersey is really gonna like revenue and profits.

Also, given the amount of money spent on Ultra, and the fact that it is the final product to come out of Vision Care R&D it will likely be a huge beacon on Valeant's profitability.
If Ultra sales are strong by the end of the summer, buy Valeant. If they are soft, the house of cards will collapse. Neither Bausch or Valeant can survive without Ultra (it will be 5-10% of Valeant's Revenues by 2016) and it will be the calling card that gets salesmen back into the ODs office.
Click to expand...
5-10% of Valeant's revenue by 2016 ??!!! Do you smoke meth or PCP ?
I doubt Valeant has any one product that represents even 5% of total revenue.
 






Anonymous said:
It is funny how you think you know everything. But you don't

PV2 was a stop gap, BTOD is a different market segment, and is not a failure.

Zeus=Ultra, always has been. Zeus was the code name gimmick from a guy with a god complex. Ultra is the name that customers will know it buy. But Valeant wasn't smart enough to understand code names, so they started talking about Zeus in the news.
If Ultra is a failure, B+L Vision Care is dead. But short of a massive recall Ultra will be huge (for Bausch). Might not make us #1 in SiHy manufacturer, but it will be much bigger than PV/PV2 ever was, for a fraction of the cost to manufacture, but at a higher retail price. New Jersey is really gonna like revenue and profits.

Also, given the amount of money spent on Ultra, and the fact that it is the final product to come out of Vision Care R&D it will likely be a huge beacon on Valeant's profitability.
If Ultra sales are strong by the end of the summer, buy Valeant. If they are soft, the house of cards will collapse. Neither Bausch or Valeant can survive without Ultra (it will be 5-10% of Valeant's Revenues by 2016) and it will be the calling card that gets salesmen back into the ODs office.
Click to expand...

I guess that will be 0.05% of revenue if Valeant buys Allergan. Spreadbet baby.
 
























"March 2014 — End-of-day comfort for contact lens wearers was one of the goals during the development of the new Ultra contact lenses by Bausch + Lomb, especially after a long day of using computers and other digital devices.

The monthly replacement lenses are made of silicone hydrogel and are manufactured using the company's MoistureSeal Technology. Ultra contact lenses are available in certain areas now and will continue to roll out nationwide this spring."

Roll-out will also continue this summer, fall and winter. At a future date, it may be available if opticians need more than one trial set.

Commercial are following the "Unicorn" strategy. We'd all love to see one for real. The plan is to increase customer aspiration to buy an Ultra lens in the future - without B+L actually having to supply any !! Valeant can book future sales against projected demand. That's how the business works in 2014 !!!!
 












Rumor is J&J are getting ready to buy B+L from Valeant just to get their hands on the Ultra lens. Market reaction has been phenomenal. This lens is proving to be a game changer just like the one day lens introduction by J&J that kicked Bausch's a** over 20 years ago.

J&J must buy B+L soon, or they will be wiped out in the contact lens market. Ultra is projected to dominate the market by Q4 2014.
 






Anonymous said:
Rumor is J&J are getting ready to buy B+L from Valeant just to get their hands on the Ultra lens. Market reaction has been phenomenal. This lens is proving to be a game changer just like the one day lens introduction by J&J that kicked Bausch's a** over 20 years ago.

J&J must buy B+L soon, or they will be wiped out in the contact lens market. Ultra is projected to dominate the market by Q4 2014.
Click to expand...

Just say no to drugs.
 






Anonymous said:
Rumor is J&J are getting ready to buy B+L from Valeant just to get their hands on the Ultra lens. Market reaction has been phenomenal. This lens is proving to be a game changer just like the one day lens introduction by J&J that kicked Bausch's a** over 20 years ago.

J&J must buy B+L soon, or they will be wiped out in the contact lens market. Ultra is projected to dominate the market by Q4 2014.
Click to expand...

Not sure if this is some type of parody post, but either way, you provided me with a morning chuckle.
If you are serious, put down the crack pipe and Kool aid.
 












I guess domination is scheduled for 2015. Who collected bonus for claiming launch in 2013 ?


http://www.democratandchronicle.com...09/08/new-bl-contacts-bing-new-jobs/15278827/


Chances are good you can't get your hands on Bausch + Lomb Inc.'s new Ultra monthly contact lens.

The eye-care company has only one manufacturing line producing them, at its North Goodman Street plant. The lenses are available only in the United States, and even there not nationwide. And demand so far is outstripping supply.

"We're selling every lens we can make," said J. Michael Pearson, CEO of B+L parent company Valeant Pharmaceutics International Inc.

But all of that is changing. B+L and parent company Valeant Pharmaceuticals International Inc. on Monday cut the ribbon on what will become a major manufacturing addition to the company's Rochester plant.

Along with the two Ultra manufacturing lines being installed there, which will bring roughly 120 jobs, B+L will put in a third and fourth, which will mean an additional 120 positions atop those, Pearson said Monday during a ceremonial ribbon cutting.

Two of the lines are expected to be up and operational by the end of 2015. The company does not yet have a timeframe for the third and fourth Ultra lines.

B+L Vision Care general manager Mark McKenna said Ultra should be available nationwide by early 2015.

And the silicone hydrogel monthly lens is only the first of an array of Ultra lens products B+L is launching, including toric and multifocal lenses, he said.

"It's not just the one product," McKenna said. "It's a matter of how quickly we can ramp up."
 




































Top Bottom
Back
Quote